7 completed, 3 terminated, 2 active not recruiting, 1 recruiting. 10 Phase 2, 7 Phase 1, 2 Phase 3.
Follow Relapsed Diffuse Large B-cell Lymphoma: new trials by email Literature Review of Relapsed Diffuse Large B-cell Lymphoma trials Research Report on Relapsed Diffuse Large B-cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab Ociperlimab, Tislelizumab, Rituximab - Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Completed | BeiGene | 53 | 2022-04-25 | 2025-09-15 |
| Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post Transplant loncastuximab tesirine - Relapsed Diffuse Large B-cell Lymphoma | Phase 2 | Withdrawn | Barbara Ann Karmanos Cancer Institute | 2022-04-08 | 2023-11-01 | |
| Copanlisib Plus Venetoclax in R/R DLBCL Copanlisib, Venetoclax - Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 48 | 2021-09-08 | 2026-01-07 |
| Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib Zanubrutinib - Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma | Phase 2 | Completed | BeiGene | 65 | 2021-08-11 | 2026-03-25 |
| DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma DPX-Survivac, Pembrolizumab, CPA - Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma | Phase 2 | Recruiting | ImmunoVaccine Technologies, Inc. (IMV Inc.) | 102 | 2021-06-18 | 2023-04-07 |
| Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) Polatuzumab Vedotin, Mabthera, Ifosfamide - Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 3 | Completed | GWT-TUD GmbH | 306 | 2021-04-30 | 2026-06-10 |
| Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL Sintilimab - Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma | Phase 2 | Unknown | Qian Wenbin | 51 | 2020-12-10 | 2020-12-09 |
| Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Loncastuximab Tesirine, Rituximab, Gemcitabine - Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 3 | Active not recruiting | ADC Therapeutics S.A. | 440 | 2020-09-16 | 2026-04-28 |
| A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma INCB053914, INCB050465 - Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | Incyte Corporation | 9 | 2018-12-03 | 2020-11-10 |
| PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma MT-3724, Gemcitabine, Oxaliplatin - Non-hodgkin Lymphoma,B Cell, Refractory Diffuse Large B-Cell Lymphoma | Phase 2 | Terminated | Molecular Templates, Inc. | 8 | 2018-08-20 | 2022-08-16 |
| Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL Ipilimumab, Nivolumab - Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | Icahn School of Medicine at Mount Sinai | 6 | 2018-05-14 | 2023-02-15 |
| Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy Atezolizumab, Rituximab, Gemcitabine 1000 mg - Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma | Phase 2 | Terminated | University Hospital Southampton NHS Foundation Trust | 53 | 2018-05-09 | 2022-08-22 |
| A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma 400mg ABT-199, Ibrutinib, Rituximab - Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Terminated | Hackensack Meridian Health | 10 | 2017-09-05 | 2024-09-23 |
| Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma Axicabtagene Ciloleucel, Fludarabine, Cyclophosphamide - Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Completed | Kite, A Gilead Company | 307 | 2015-04-21 | 2024-06-04 |
| Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Ibrutinib, Lenalidomide, Rituximab - Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Completed | Pharmacyclics LLC. | 138 | 2014-03-13 | 2022-02-04 |
Lymphoma, Large B-Cell, Diffuse (15) · Lymphoma (2) · Lymphoma, Non-Hodgkin (1) · Neoplasms (1) · Recurrence (1)
Hemic and Lymphatic Diseases (15) · Immune System Diseases (15) · Immunoproliferative Disorders (15) · Lymphatic Diseases (15) · Lymphoma, B-Cell (15) · Lymphoproliferative Disorders (15) · Neoplasms by Histologic Type (15) · Lymphoma, Non-Hodgkin (14) · Neoplasms (14) · Lymphoma (13) · Disease Attributes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Rituximab (7) · Gemcitabine (4) · Oxaliplatin (4) · Carboplatin (2) · Cyclophosphamide (2) · Etoposide (2) · Ifosfamide (2) · ibrutinib (2) · loncastuximab tesirine (2) · venetoclax (2) · Bendamustine Hydrochloride (1) · Cisplatin (1) · Dexamethasone (1) · Doxorubicin (1) · Ipilimumab (1)
BeiGene (2) · ADC Therapeutics S.A. (1) · Barbara Ann Karmanos Cancer Institute (1) · Dana-Farber Cancer Institute (1) · GWT-TUD GmbH (1) · Hackensack Meridian Health (1) · Icahn School of Medicine at Mount Sinai (1) · ImmunoVaccine Technologies, Inc. (IMV Inc.) (1) · Incyte Corporation (1) · Kite, A Gilead Company (1) · Molecular Templates, Inc. (1) · Pharmacyclics LLC. (1) · Qian Wenbin (1) · University Hospital Southampton NHS Foundation Trust (1)
United States (10) · China (4) · United Kingdom (4) · Canada (3) · France (3) · Germany (3) · Spain (3) · Belgium (2) · Hungary (2) · Israel (2) · Netherlands (2) · Poland (2) · Argentina (1) · Australia (1) · Austria (1)
Andre Goy, MD (1) · Andy Davies (1) · Dipenkumar Modi, M.D. (1) · Fred Zheng, MD (1) · Jennifer Crombie, MD (1) · Joshua Brody, MD (1) · Jutta K. Neuenburg, MD, PhD (1)
PMID 29226797, PMID 30518502, PMID 31331917, PMID 33035333, PMID 33334730, PMID 34296427, PMID 34310745, PMID 34493319, PMID 34515338, PMID 36618900, PMID 36821768, PMID 38635762, PMID 39240498
2015 (1), 2016 (1)